Figure 1

(A) CD3+ infiltrating T-lymphocytes surrounding the follicular CBCL lesion. Magnification × 10. (B and C) Proliferation status of the tumour cells as determined by ki-67 staining before (B) and during (C) therapy with rituximab. Magnification × 20. (D–F) Expression status of CD20 in relapsed CBCL before (D) and during (E and F) rituximab treatment. Magnification × 40. (G–I) RKIP expression at primary diagnosis (G) and during (H and I) therapy with rituximab. Magnification × 40. (J–L) Expression of antiapoptotic bcl-2 in recurring CBCL at diagnosis (J) and during rituximab application (K and L). Magnification × 40.